Klertis

Sunitinib, the active ingredient in Klertis, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It treats adult patients with renal cell carcinoma, gastrointestinal stromal tumor, and pancreatic neuroendocrine tumor by targeting tumor growth pathways.

GNH USA supplies Klertis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Klertis (sunitinib) is indicated for malignancies that depend on receptor tyrosine‑kinase signaling.

Renal cell carcinoma: slows disease progression and extends survival in advanced cases. Gastrointestinal stromal tumor: inhibits tumor growth after failure of first‑line therapy. Pancreatic neuroendocrine tumor: reduces tumor size and delays disease progression.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may require fluid replacement. - Nausea: feeling of sickness often managed with anti‑emetics. - Hand‑foot syndrome: redness or swelling of palms and soles. - Hypertension: elevated blood pressure requiring monitoring. - Decreased appetite: reduced desire to eat.

Serious or Rare Side Effects: - Cardiac dysfunction: reduced left‑ventricular ejection fraction. - Liver toxicity: elevated transaminases or bilirubin. - Hemorrhage: bleeding events, including gastrointestinal. - Thromboembolic events: deep‑vein thrombosis or pulmonary embolism. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Neutropenia: low white‑blood‑cell count increasing infection risk.

Patients should be evaluated for specific risks before initiating therapy.

Baseline cardiac assessment: perform echocardiogram or MUGA scan. Blood pressure monitoring: check regularly and treat hypertension promptly. Liver function tests: assess before and during treatment. Hematologic monitoring: complete blood count to detect cytopenias. Avoid concurrent strong CYP3A4 inhibitors: may increase sunitinib exposure. Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and light.

Sunitinib may interact with other medicines that affect its metabolism or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can raise sunitinib levels. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Anticoagulants (e.g., warfarin): increased bleeding risk.

Moderate Interactions (Monitor Closely): - CYP2C9 substrates (e.g., phenytoin): possible altered plasma concentrations. - Antihypertensives: may need dose adjustment due to blood‑pressure effects. - CYP3A4 substrates with narrow therapeutic index (e.g., tacrolimus): monitor drug levels.